These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
394 related articles for article (PubMed ID: 18467578)
1. AIDS/HIV. A STEP into darkness or light? Moore JP; Klasse PJ; Dolan MJ; Ahuja SK Science; 2008 May; 320(5877):753-5. PubMed ID: 18467578 [No Abstract] [Full Text] [Related]
2. New hope for an AIDS vaccine. Robinson HL Nat Rev Immunol; 2002 Apr; 2(4):239-50. PubMed ID: 12001995 [TBL] [Abstract][Full Text] [Related]
3. AIDS research. Did Merck's failed HIV vaccine cause harm? Cohen J Science; 2007 Nov; 318(5853):1048-9. PubMed ID: 18006711 [No Abstract] [Full Text] [Related]
4. Disappointing data scuttle plans for large-scale AIDS vaccine trial. Cohen J Science; 2002 Mar; 295(5560):1616-7. PubMed ID: 11872804 [No Abstract] [Full Text] [Related]
5. India targets local HIV strain in test of AIDS vaccine. Jayaraman KS Nature; 2004 Jan; 427(6971):185. PubMed ID: 14724601 [No Abstract] [Full Text] [Related]
6. Candidate AIDS vaccines. Graham BS; Wright PF N Engl J Med; 1995 Nov; 333(20):1331-9. PubMed ID: 7566026 [No Abstract] [Full Text] [Related]
7. [Nucleic acid vaccines for study in AIDS patients are approved. Vaccines of genetic molecules--humoral and cellular immune response]. Hobom B Fortschr Med; 1995 Dec; 113(35-36):12. PubMed ID: 8582688 [No Abstract] [Full Text] [Related]
8. Merck's HIV vaccine flop brings vectors under closer scrutiny. Ledford H Nat Biotechnol; 2008 Jan; 26(1):3-4. PubMed ID: 18182999 [No Abstract] [Full Text] [Related]
9. HIV vaccine efficacy trials: towards the future of HIV prevention. Kim D; Elizaga M; Duerr A Infect Dis Clin North Am; 2007 Mar; 21(1):201-17, x. PubMed ID: 17502236 [TBL] [Abstract][Full Text] [Related]
10. HIV-1/AIDS vaccine development: are we in the darkness. Qiu C; Xu JQ Chin Med J (Engl); 2008 May; 121(10):939-45. PubMed ID: 18706210 [No Abstract] [Full Text] [Related]
11. HIV-1 T-cell vaccines: evaluating the next step. Pantaleo G Lancet Infect Dis; 2008 Feb; 8(2):82-3. PubMed ID: 18060842 [No Abstract] [Full Text] [Related]
12. AIDS vaccine: efficacy, safety and ethics. Veljkovic V; Veljkovic N; Glisic S; Ho MW Vaccine; 2008 Jun; 26(24):3072-7. PubMed ID: 18164521 [TBL] [Abstract][Full Text] [Related]
15. Tepid endorsement for HIV vaccine trial. Science; 1995 Feb; 267(5200):966. PubMed ID: 7863340 [No Abstract] [Full Text] [Related]
16. Adenovirus as vector for HIV: efficacy and safety issues. Natuk RJ; Wade MS; Chengalvala M; Murthy KK; Chanda PK; Murthy SC; Bhat BM; Bhat R; Dheer SK; Mizutani S Dev Biol Stand; 1995; 84():153-6. PubMed ID: 7796948 [No Abstract] [Full Text] [Related]
17. AIDS research. Debate begins over new vaccine trials. Cohen J Science; 2001 Sep; 293(5537):1973. PubMed ID: 11557856 [No Abstract] [Full Text] [Related]
18. [The virus can not yet be eradicated. "HIV-infected patients cannot be completely cured"]. Hellbom K Krankenpfl J; 1998; 36(7-8):274. PubMed ID: 9775853 [No Abstract] [Full Text] [Related]
19. [AIDS vaccine: who should be selected for the test?]. Marcus U Fortschr Med; 1995 Nov; 113(32):16-7. PubMed ID: 8543269 [No Abstract] [Full Text] [Related]
20. The rational design of an AIDS vaccine. Douek DC; Kwong PD; Nabel GJ Cell; 2006 Feb; 124(4):677-81. PubMed ID: 16497577 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]